Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir

Emcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention and treatment. This royalty-free agreement focuses on increasing access to the drug in 120 countries, especially resource-limited nations. Emcure aims to provide high-quality, low-cost HIV medication to improve health outcomes globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0jB2cKg
via IFTTT